Alessandro Lozza

Alessandro Lozza

Auto-generated profile, based on publicly available information

Alessandro Lozza

Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2013 in JAMA
Verified
Journal Article
Open access
PDF file
JBJohn L. Berk
John L. Berk
OSOle B. Suhr
Ole B. Suhr
LOLaura Obici
Laura Obici
YSYoshiki Sekijima
Yoshiki Sekijima
SZSteven R. Zeldenrust
Steven R. Zeldenrust
FCfor the Diflunisal Trial Consortium
for the Diflunisal Trial Consortium
Hereditary transthyretin amyloidosis (ATTR) is a lethal, autosomal dominant genetic disease caused by the aggregation of variant and wild-type transthyretin (TTR), a thyroxine transport protein predominantly produced by the liver.1,2 More than 100 different mutations in the TTR gene destabilize its tetrameric structure, promoting TTR dissociation and misassembly into oligomeric aggregates including amyloid fibrils.3,4 The process of TTR amyloidogenesis produces a spectrum of debilitating disease ranging from pure polyneuropathy (transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) to selective heart involvement.5,6 In ATTR-FAP, small- and large-fiber injury induce sensory and autonomic deficits accompanied by motor weakness in a length-dependent fashion, mimicking manifestations of diabetic polyneuropathy. Untreated, patients exhibit progressive neurological deficits, dying 10 to 15 years after disease presentation.7 Fewer than 10 000 people are estimated to be clinically affected worldwide.8

2 May 2012 in Amyloid
Verified
Journal Article
Closed access
LOLaura Obici
Laura Obici
ACAndrea Cortese
Andrea Cortese
ALAlessandro Lozza
Alessandro Lozza
JLJacopo Lucchetti
Jacopo Lucchetti
MGMarco Gobbi
Marco Gobbi
GMGiampaolo Merlini
Giampaolo Merlini
We designed a phase II, open-label study to evaluate the efficacy, tolerability, safety, and pharmacokinetics of orally doxycycline (100 mg BID) and tauroursodeoxycholic acid (TUDCA) (250 mg three times/day) administered continuously for 12 months. Primary endpoint is response rate defined as nonprogression of the neuropathy and of the cardiomyopathy. Since July 2010, we enrolled 20 patients. Seventeen patients have hereditary ATTR, two patients have senile systemic amyloidosis, and one is a domino recipient. Seven patients completed 12-month treatment, 10 completed 6-month treatment, two discontinued because of poor tolerability, and one is lost at follow-up. No serious adverse events were registered. No clinical progression of cardiac involvement was observed. The neuropathy (Neuropathy Impairment Score in the Lower Limbs [NIS-LL] and Kumamoto score) remained substantially stable over 1 year. These preliminary data indicate that the combination of Doxy-TUDCA stabilizes the disease for at least 1 year in the majority of patients with an acceptable toxicity profile.

1 October 2012 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
FBF. Biglioli
F. Biglioli
VCV. Colombo
V. Colombo
FTF. Tarabbia
F. Tarabbia
MPM. Pedrazzoli
M. Pedrazzoli
VBV. Battista
V. Battista
AFA. Frigerio
A. Frigerio

16 September 2009 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
EAE Alfonsi
E Alfonsi
IMI M Merlo
I M Merlo
MPM Ponzio
M Ponzio
CMCristina Montomoli
Cristina Montomoli
CTC Tassorelli
C Tassorelli
EME Martignoni
E Martignoni
Objectives: Botulinum toxin (BTX) injection into the cricopharyngeal (CP) muscle has been proposed for the treatment of neurogenic dysphagia due to CP hyperactivity. The aim was to determine whether an electrophysiological method exploring oropharyngeal swallowing could guide treatment and discriminate responders from non-responders, based on the association of CP dysfunction with other electrophysiological abnormalities of swallowing. Methods: Patients with different neurological disorders were examined: Parkinson disease, progressive supranuclear palsy, multiple system atrophy-Parkinson variant, multiple system atrophy cerebellar variant, stroke, multiple sclerosis and ataxia telangiectasia. All patients presented with clinical dysphagia, and with complete absence of CP muscle inhibition during the hypopharyngeal phase of swallowing. Each patient underwent clinical and electrophysiological investigations before and after treatment with BTX into the CP muscle of one side (15 units of Botox). Clinical and electrophysiological procedures were performed in a blind manner by two different investigators. The following electrophysiological measures were analysed: (1) duration of EMG activity of suprahyoid/submental muscles (SHEMG-D); (2) duration of laryngopharyngeal mechanogram (LPM-D); (3) duration of the inhibition of the CP muscle EMG activity (CPEMG-ID); and (4) interval between onset of EMG activity of suprahyoid/submental muscles and onset of laryngopharyngeal mechanogram (I-SHEMG-LPM). Results: Two months after treatment, 50% of patients showed a significant improvement. Patients with prolonged or reduced SHEMG-D values and prolonged I-SHEMG-LPM values did not respond to BTX. Therefore, values for which BTX had no effect (warning values) were identified. Conclusions: This electrophysiological method can recognise swallowing abnormalities which may affect the outcome of the therapeutic approach to dysphagia with BTX treatment.

16 March 2016 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ACA. Cortese
A. Cortese
GVG. Vita
G. Vita
Marco LuigettiMarco Luigetti
Marco Luigetti
Massimo RussoMassimo Russo
Massimo Russo
GBG. Bisogni
G. Bisogni
DPDavide Pareyson
Davide Pareyson

1 November 2008 in Clinical Neurophysiology
Verified
Journal Article
Closed access
SRSabrina Ravaglia
Sabrina Ravaglia
ACAlessandro Corso
Alessandro Corso
GPGiovanni Piccolo
Giovanni Piccolo
ALAlessandro Lozza
Alessandro Lozza
EAEnrico Alfonsi
Enrico Alfonsi
ACAlfredo Arturo Costa
Alfredo Arturo Costa